Drug intelligence / Profile preview

LIPO-6T

Development stage: Discontinued
Lead developer: ANRS
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Injection

Overview

LIPO-6T is an HIV lipopeptide vaccine component used in therapeutic vaccination strategies for HIV-1 infection. It is administered in combination with ALVAC-HIV (vCP1433) and interleukin-2 (IL-2) to enhance HIV-specific immune responses, including CD4+ and CD8+ T cell responses, with the aim of improving viral control after antiretroviral therapy discontinuation. Clinical trials have evaluated its impact on immune responses and viral replication in patients treated early during primary HIV-1 infection and in chronically infected patients.

Other names: HIV Lipopeptides

Targets

HIV-1 antigens

Beyond the preview

Go deeper on LIPO-6T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIPO-6T.

Explore the full profile